Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma
Glioblastoma is the most common primary central nervous system malignancy and has a poor prognosis. Standard first-line treatment, which includes surgery followed by adjuvant radio-chemotherapy, produces only modest benefits to survival1,2. Here, to explore the feasibility, safety and immunobiologic...
Hlavní autoři: | , , , , , , , , , , , , , , , , , , , |
---|---|
Médium: | info:eu-repo/semantics/article |
Jazyk: | eng |
Vydáno: |
Nature Publishing Group
2024
|
Témata: | |
On-line přístup: | https://hdl.handle.net/10171/68722 |